Prevention and Treatment of Opportunistic Infections in People With HIV

Presenter

Henry Masur, MD
George Washington University
Washington D.C

Moderator

Judith S. Currier, MD
University of California Los Angeles

July 15, 2024

10:00 AM – 11:15 AM PT

Overview

Assessment of Needs

People with HIV-associated immunosuppression and people with HIV who are not on antiretroviral therapy can be at increased risk of opportunistic infections caused by viruses, bacteria, fungi, and protozoa. This webinar provides an update on what clinicians need to know regarding the prevention and treatment of common opportunistic infections in people with HIV.

Learning Objectives

On completion of this activity, learners will be able to:

  • Identify reasons for continued morbidity due to HIV-related opportunistic infections
  • Describe the role of molecular diagnostics for selected HIV-related infectious diseases
  • Assess options for the treatment of HIV-related cryptococcal meningitis and other common opportunistic infections

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Monday, July 15, 2024, 10:30 AM (PT).

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Masur reported no financial relationships with ineligible companies. (Updated May 22, 2024)

Moderator

Dr Currier reported consulting fees from Merck & Co, Inc (Updated March 6, 2024)

Planner/Reviewer

Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies (Updated May 15, 2024)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies (Updated May 22, 2024)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/ 

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.

Nursing Credits

This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoThis activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.